Cardiologists want solid proof of AI’s efficacy and value. And even then, obstacles to acceptance may remain.

Do you remember the anticipation around renal denervation? And then the ACC.14 presentation of the SYMPLICITY HTN-3 results, where the excitement about a new way to treat resistant hypertension seemed to crash?

Smart technologies are often touted as the answer to some of cardiology’s greatest challenges. But where does hyperbole end and reality begin?